Welcome to our dedicated page for Blade Air Mobility SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Strata Critical Medical, Inc., formerly Blade Air Mobility, Inc., files regulatory documents that document the company's transition from a broader air mobility platform to a critical medical business. The filings cover the completed Passenger business disposition, the corporate name change, Nasdaq-listed common stock under SRTA, and warrant-related capital-structure actions, including a Form 25 for removal of warrants from listing and registration.
Its 8-K reports and proxy materials disclose operating results from continuing operations, logistics and clinical revenue categories, material agreements, acquisition activity, credit arrangements involving operating subsidiaries such as Trinity Air Medical and Keystone Perfusion Services, and annual meeting governance matters. The record also includes exhibit filings, Inline XBRL cover data, and stockholder voting disclosures tied to the rebranded issuer.
Strata Critical Medical (SRTA): Co-CEO, General Counsel, and Director Melissa M. Tomkiel exercised employee stock options and acquired 27,778 shares of Class A common stock at $0.18 per share on 11/07/2025 (transaction code M). Following the transaction, she beneficially owns 1,400,420 shares, held directly.
The exercised options relate to grants first exercisable on 05/07/2021 and expiring on 07/28/2030. After this activity, 276,960 stock options remain beneficially owned, held directly.
Strata Critical Medical (formerly Blade) reported Q3 2025 results highlighting a strategic pivot to healthcare services. Revenue from continuing operations reached $49,298 (vs. $36,062 a year ago), while operating loss narrowed to $5,622. The quarter’s net income of $57,416 was driven by discontinued operations following the Passenger business sale.
On August 29, Strata sold its Passenger business to a Joby Aviation subsidiary for consideration valued at $75,357 in Joby shares and later sold those shares for net proceeds of $70,163. The company may receive up to an additional $35,000 based on performance and retention targets, plus up to $10,000 in indemnity holdbacks. On September 16, Strata acquired Keystone Perfusion Services for $109,963 in cash and 3,434,609 shares valued at $16,828, adding $69,067 of goodwill and $42,600 of identifiable intangibles.
Cash and cash equivalents were $22,753 and short‑term investments were $53,165 as of September 30, 2025. Basic and diluted EPS were $0.70, reflecting a continuing operations loss of $0.12 and discontinued operations income of $0.81. Shares outstanding were 86,366,526 as of November 3, 2025.
Strata Critical Medical, Inc. furnished a Form 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The disclosure is provided under Item 2.02, Results of Operations and Financial Condition, and is designated as furnished, not filed, under the Exchange Act.
Strata Critical Medical, Inc. reported insider equity activity by its Chief Accounting Officer, Amir Cohen. On 10/31/2025, Cohen acquired 41,786 shares at $0 upon certification of performance criteria tied to previously granted PSUs. On 11/03/2025, 20,497 shares were withheld by the company at $5.03 to cover taxes related to that vesting. Following these transactions, Cohen directly owned 121,342 shares.
Strata Critical Medical, Inc. (SRTA) reported insider equity changes by Co‑CEO, General Counsel, and Director Melissa M. Tomkiel. On 10/31/2025, she acquired 208,929 shares of Class A common stock at $0, reflecting certification of performance-based restricted stock units (PSUs). On 11/03/2025, 106,659 shares were disposed under code F at $5.03, representing shares withheld to satisfy tax obligations upon PSU vesting. Following these transactions, she beneficially owns 1,372,642 shares, held directly.
Strata Critical Medical, Inc. (SRTA): Director and Co-CEO/CFO William A. Heyburn reported equity changes on Form 4. On 10/31/2025, he acquired 181,072 shares of Class A common stock at $0 upon the Compensation Committee’s certification of performance criteria for PSUs granted on March 8, 2024. Following this, his beneficial ownership was 1,486,569 shares (direct).
On 11/03/2025, 100,133 shares were disposed of at $5.03 under transaction code “F,” reflecting shares withheld by the issuer to satisfy tax withholding obligations related to the PSU vesting. After these transactions, his beneficial ownership stood at 1,386,436 shares (direct).
Strata Critical Medical, Inc. reported an insider transaction by Co-CEO, General Counsel, and Director Melissa M. Tomkiel. On 10/22/2025, she exercised stock options (transaction code M) for 55,556 shares of Class A common stock at $0.18 per share and acquired the same number of shares.
After the transaction, she directly beneficially owned 1,270,372 shares. Her remaining derivative holdings included 304,738 stock options outstanding, originally exercisable from 05/07/2021 and expiring on 07/28/2030.
Strata Critical Medical (SRTA) reported an insider transaction: Co‑CEO and General Counsel Melissa M. Tomkiel exercised stock options (code M) for 55,555 Class A shares at $0.18 on 10/10/2025.
Following the transaction, she beneficially owned 1,214,816 shares directly, and held 360,294 stock options outstanding. The option grant was originally exercisable from 05/07/2021 and expires 07/28/2030.
Strata Critical Medical, Inc. completed the acquisition of Keystone Perfusion Services, LLC on September 16, 2025. The buyer paid a base Purchase Price of $124 million (subject to adjustment), with payment structured eighty percent in cash and twenty percent in Strata common stock, plus up to $23 million of contingent consideration tied to performance over the next 12, 24 and 36 months.
The Purchase Price can be adjusted downward or upward by up to $12.4 million based on Keystone's 2025 adjusted EBITDA relative to specified thresholds. At Closing, after adjustments and expenses, Seller received roughly 88% cash and 12% stock. Strata issued 3,434,607 shares in reliance on exemptions from registration and obtained representation and warranty insurance as primary recourse for certain breaches. The filing includes a standard cautionary note on forward-looking statements and lists customary surviving reps, warranties and covenants.
Robert S. Wiesenthal, a director of Strata Critical Medical, Inc. (ticker: SRTA), reported a grant of 40,607 restricted stock units (RSUs) on 08/29/2025 that will be settled in common stock upon vesting. The RSUs are valued at $0 in the filing and 100% of these RSUs vest on the date of the company's 2026 Annual Meeting of Stockholders. The filing states the reporting person beneficially owns 5,275,662 shares following the reported transaction as direct ownership. The filing also discloses that, effective September 2, 2025, the issuer amended the terms of previously granted unvested RSUs totaling 886,886 and 33,591 units to add an additional performance-related vesting condition, and those units are no longer included in the beneficial ownership total until the performance condition is met. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Wiesenthal.